Mr. Yachin has served as a member of our Board of Directors since May, 2018. He is a biotechnology executive and brings to the board extensive experience in drug development, immunotherapy, and cell therapy.

Mr. Yachin is currently the Chief Executive Officer and Executive Chairman of Xerient (2019-present), a drug development company focused on enhancing radiation therapy. Previously, he served as Chief Executive Officer of Serpin Pharma (2013-2019), an immunotherapy company based in Virginia, and Chief Executive Officer of Nasvax (2011-2013), a company specializing in immunotherapeutics and vaccine development.

He has also served as Chief Executive Officer of Vessl Ltd. (2007-2011), a cell therapy company focused on blood vessel disorders, where he led clinical studies in the U.S. and Israel, multiple financing rounds, and a strategic partnership with Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Yachin was the founder and Chief Executive Officer of Chiasma Inc. (Nasdaq: CHMA), a biotechnology company focused on oral delivery of macromolecule drugs. During his six-year tenure, from 2001 to 2007, he established the company’s operations in Israel and the U.S., secured multiple financing rounds, and guided corporate strategy and operations.

Earlier in his career, Mr. Yachin served as Chief Executive Officer of Naiot Technological Center Ltd., where he provided seed funding and strategic guidance to over a dozen biomedical startups, including Remon Medical (acquired by Boston Scientific) and Enzymotec (Nasdaq: ENZY).

Mr. Yachin holds a B.Sc. in Industrial Engineering and Management and an M.B.A. from the Technion – Israel Institute of Technology.

Dr. Mogelsvang has served as our President, Chief Executive Officer, and a member of our Board of Directors since June, 2017. He is a biotechnology executive and entrepreneur with over 25 years of industry experience. Prior to joining the Company, Dr. Mogelsvang was the President and Chief Executive Officer of Peak Pharmaceuticals, where he led the Company from its inception to a profitable veterinary health business. He also co-founded Serpin Pharma, a clinical-stage biotechnology company, serving as Vice President of Research and Development, and Caerus Discovery, an immunology-focused biotechnology company supported by BioWa – Kyowa Hakko Kirin and ImmunoCellular Therapeutics, where he served as Head of Research and Development. Additionally, he is the founder of Exxel Pharma and has been involved in multiple other biotechnology ventures.

Dr. Mogelsvang holds a Ph.D. in Biochemistry from the University of Cambridge and an M.Sc. in Plant Molecular Biology from the University of Copenhagen.